Abrdn Healthcare Investors
NYSE:HQHAsset Management
+$0.15 today
- Market cap
- $1.27B
- Beta
- 0.76
- P/E (TTM)
- 4.2
- EPS (TTM)
- $4.72
- Dividend yield
- 11.57%
Volume 0.23M
Average 0.14M
HQH EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Abrdn Healthcare InvestorsNYSE: HQH
EBITDA · Q4 FY2025 · quarter ended Sep 2025
EBITDA of $173.45M in Q4 FY2025
Q4 FY2025 EBITDA was $173.45M.
Context
- EBITDA amounted to 98.8% of revenue in FY2025, up 98.8 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 98.61M USD
- Year-over-year change
- —
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 98.61M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
EBITDA vs competitors
How HQH compares with its peers on the latest reported figures
- HQH's FY2025 EBITDA of $98.61M is the 6th highest of the 10 companies compared; the peer median is $104.38M.
- EBITDA amounts to 98.8% of revenue for HQH, versus a peer median of 49.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $384.75M | -13.6% | +7.9% | 48.1% | |
| LTM Mar 2026 | $196.46M | +44.0% | — | 71.2% | |
| LTM Mar 2026 | $161.52M | +55.8% | +22.4% | 65.9% | |
KBDCKayne Anderson BDC, Inc. | LTM Mar 2026 | $129.71M | +1.6% | +55.4% | 65.6% |
| LTM Mar 2026 | $104.38M | +34.5% | +23.6% | 48.1% | |
| FY2025 | $98.61M | — | — | 98.8% | |
| LTM Mar 2026 | $97.43M | -17.0% | +19.9% | 49.5% | |
| LTM Mar 2026 | $87.48M | +3.4% | +100.1% | 49.2% | |
| LTM Mar 2026 | $83.22M | -25.5% | +53.6% | 36.9% | |
| LTM Mar 2026 | $31.77M | +196.0% | — | 42.5% | |
| Peer median (excluding HQH) | $104.38M | +3.4% | +23.6% | 49.2% | |
Competitors are the stored peer set for HQH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.48M | 8.27M | 10.29M | 10.77M | 99.81M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 6.48M | 8.27M | 10.29M | 10.77M | 99.81M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 12.71M | 11.94M | 11.48M | 10.99M | 1.14M |
| Operating Expenses | 12.71M | 11.94M | 11.48M | 10.99M | 1.2M |
| Depreciation & Amortization | 6.23M | 3.67M | 1.19M | 220.27K | 0 |
| EBITDA | 0 | 0 | 0 | 0 | 98.61M |
| EBITDA Margin | 0.0% | 0.0% | 0.0% | 0.0% | 98.8% |
| Operating Income | (6.23M) | (3.67M) | (1.19M) | (220.27K) | 98.61M |
| Operating Margin | -96.1% | -44.4% | -11.5% | -2.0% | 98.8% |
| Interest Income | 0 | 112.31K | 620.01K | 2.02M | 1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 161.41M | (190.56M) | 57.52M | 185.17M | 0 |
| Income Before Tax | 155.18M | (194.23M) | 56.33M | 184.95M | 98.61M |
| Pre-Tax Margin | 2394.6% | -2348.4% | 547.4% | 1717.4% | 98.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 155.18M | (194.23M) | 56.33M | 184.95M | 98.61M |
| Net Margin | 2394.6% | -2348.4% | 547.4% | 1717.4% | 98.8% |
| EPS (Basic) | 3.49 | (4.10) | 1.14 | 3.55 | 1.84 |
| EPS (Diluted) | 3.49 | (4.10) | 1.14 | 3.55 | 1.84 |
| Weighted Avg Shares | 45.43M | 47.34M | 49.44M | 52.13M | 53.63M |
| Weighted Avg Shares (Diluted) | 45.43M | 47.34M | 49.44M | 52.13M | 53.63M |
Abrdn Healthcare Investors
NYSE:HQH
Intrinsic Alpha fair value
Locked
Current Price
$22.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.